Affini-T is a precision immunotherapy company focused on developing potentially curative treatments for patients with solid tumors by targeting core oncogenic driver mutations. The company's expertise lies in pinpointing highly active TCRs (T-cell receptors) directed at crucial tumor biology elements such as KRAs (Kirsten rat sarcoma viral oncogene homolog) and p53. Through the integration of synthetic biology and gene editing technologies, Affini-T aims to overcome the challenges of the immunosuppressive tumor microenvironment, fostering a sustained anti-tumoral response. This innovative approach holds promise in revolutionizing therapies for pancreatic, colorectal, and lung cancers.
$175M • 2022 • Series B
Affini-T is dedicated to creating curative treatments for solid tumors by targeting key oncogenic mutations.
Winning pitch decks that have closed millions in investments for leading startups and billion-dollar unicorns.
Investors see 5,000 pitch decks per year. Will you stand out?
No spam. Up to 2 emails/mo – only the good stuff!